STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLOV
  4. [Form 4] CLOVER HEALTH INVESTMENTS, CORP. /DE Insider Trading Activity

Clover Health exec sells 1,921 shares at $4.56

Clover Health’s Medicare Advantage CEO reported a small Rule 10b5-1 plan sale, retaining over 2.8 million shares.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) executive Jamie L. Reynoso, CEO, Medicare Advantage, reported a sale of 1,921 shares of Class A Common Stock on September 17, 2026 at $4.56 per share in an open-market or private transaction, leaving 2,803,446 shares held directly. The sale was effected under a Rule 10b5-1 trading plan adopted on March 12, 2026.

Positive

  • None.

Negative

  • None.
Insider Reynoso Jamie L.
Role CEO, Medicare Advantage
Sold 1,921 shs ($9K)
Type Security Shares Price Value
Sale Class A Common Stock F1 1,921 $4.56 $9K
Holdings After Transaction: Class A Common Stock — 2,803,446 shares (Direct)
Footnotes (1)
  1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
Shares sold 1,921 shares Class A Common Stock sold by Jamie L. Reynoso on September 17, 2026
Sale price per share $4.56 per share Price for the Class A Common Stock sale on September 17, 2026
Shares held after transaction 2,803,446 shares Direct holdings of Jamie L. Reynoso following the reported sale
Adoption date of Rule 10b5-1 plan March 12, 2026 Trading plan under which the September 17, 2026 sale was effected
Rule 10b5-1 trading plan regulatory
"The sale reported ... was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Class A Common Stock financial
"reported a sale of Class A Common Stock on September 17, 2026"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
open-market or private transaction financial
"Sale in an open-market or private transaction on September 17, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CLOV report for Jamie L. Reynoso?
Jamie L. Reynoso reported selling 1,921 shares of Clover Health Class A Common Stock on September 17, 2026 in an open-market or private transaction at $4.56 per share, according to the Form 4.

How many CLOV shares does Jamie L. Reynoso hold after the reported sale?
After the reported sale, Jamie L. Reynoso directly holds 2,803,446 shares of Clover Health Class A Common Stock, as stated in the Form 4 filing.

Was the CLOV insider sale made under a Rule 10b5-1 trading plan?
Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by Jamie L. Reynoso on March 12, 2026, meaning the trades were pre-arranged under that plan.

What price did Jamie L. Reynoso receive per CLOV share in the sale?
The reported sale of Clover Health Class A Common Stock was executed at $4.56 per share on September 17, 2026, based on the Form 4 disclosure.

What is Jamie L. Reynoso’s role at CLOV mentioned in the Form 4?
Jamie L. Reynoso is identified as CEO, Medicare Advantage at Clover Health Investments, Corp., serving as an officer of the company in that capacity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Reynoso Jamie L.
(Last)(First)(Middle)
C/O CLOVER HEALTH INVESTMENTS, CORP.
NOT APPLICABLE
(Street)
WILMINGTON DELAWARE 19801
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CEO, Medicare Advantage
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock09/17/2026S1,921(1)D$4.562,803,446D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
Remarks:
/s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso09/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on CLOV

Trending in the feed

Open the live feed